Welcome to our dedicated page for Aspira Women's Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.
Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.
One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.
In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.
The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.
Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.
The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.
Aspira Women's Health has expanded its co-marketing and distribution collaboration with BioReference to include OvaWatch® in their portfolio. The partnership, which has included Ova1Plus® since 2022, will now market Aspira's complete OvaSuite portfolio to BioReference's healthcare provider clients. This expansion follows OvaWatch's approval by the New York State Department of Health's Clinical Laboratory Evaluation Program, making it available to over 15 million women in New York and New Jersey.
Aspira Women's Health (Nasdaq: AWH) has scheduled its Q3 2024 earnings release for Thursday, November 14, 2024. The company will discuss financial results for the three and nine months ended September 30, 2024. Management will host a conference call at 8:30 am ET to present financial results and provide a corporate update. The call will be accessible via toll-free number (877-545-0320) and international number (973-528-0002) with access code 436613. A webcast replay will be available on the company's Investor Relations website.
Aspira Women's Health (Nasdaq: AWH) announced it has been awarded $10 million over two years from the Advanced Research Projects Agency for Health (ARPA-H) as part of the Sprint for Women's Health initiative. The funding will support the development of ENDOinform™, a multi-marker blood test for endometriosis detection using AI-enabled algorithms combining protein and microRNA biomarkers. Selected as one of 23 awardees from over 1,700 submissions, Aspira received one of only six Launchpad awards for advanced-stage projects. The company expects to meet its first milestone in Q4 2024, triggering a $2 million payment. The company will host a virtual R&D Day on October 29, 2024, to discuss the development pipeline.
Aspira Women's Health (Nasdaq: AWH) has been selected to receive a $10 million award from ARPA-H's Sprint for Women's Health program. The funding, distributed over two years through milestone-based payments, will support the development of EndoMDx, a multi-marker miRNA blood test for endometriosis detection. Selected from over 1,700 submissions, Aspira will collaborate with ARPA-H Program Manager and Investor Catalyst Hub for test development and commercial launch. The project addresses a critical need, as endometriosis affects up to six million women in the US, currently requiring invasive laparoscopic surgery for diagnosis, with patients typically facing 7-10 years delay in diagnosis.
Aspira Women's Health Inc. (Nasdaq: AWH) has received approval from the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) for OvaWatch®. This non-invasive blood test assesses ovarian cancer risk in women with adnexal masses initially determined as indeterminate or benign. The CLEP approval, required for all lab-developed tests in New York, ensures compliance with state regulatory standards and includes a comprehensive review of Quality Management Systems.
CEO Nicole Sandford highlighted the significance of this approval, stating it opens doors to one of the nation's largest healthcare markets with over 10 million women in New York state. The CLEP approval is viewed as a validation of the test's rigorous science, potentially strengthening Aspira's credibility in other markets and positioning the company well for future regulatory pathways.
Aspira Women's Health (Nasdaq: AWH) has published data in Gynecologic Oncology demonstrating improved performance of its in-development blood test for assessing malignancy risk in adnexal masses. The study shows that combining miRNA with protein biomarkers, age, and menopausal status offers the most accurate classification for identifying early-stage ovarian cancer.
Key findings include:
- 92% sensitivity at 80% specificity overall
- 80% sensitivity for early-stage cancers
- 100% sensitivity for later-stage cancers
- 78% sensitivity for early-stage, serous ovarian cancers
- 82% sensitivity for early-stage, non-serous cancers
The combined model improved ROC AUC on internal (0.9) and external (0.95) validation sets compared to miRNA alone or proteins plus metadata without miRNA.
Aspira Women's Health (Nasdaq: AWH), a bio-analytical women's health company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel. CEO Nicole Sandford will deliver a presentation, available on-demand from September 9 at 7:00 am ET for registered attendees.
Company management will be available for in-person one-on-one meetings on September 10 and 11. Interested investors should contact H.C. Wainwright representatives. A replay of the presentation will be posted on the Events page of Aspira's Investors section on their website when available.
Aspira Women's Health Inc. (Nasdaq: AWH) has been selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). This designation acknowledges Aspira's position as an innovator in women's health and provides new opportunities for funding, thought leadership, and networking.
The Investor Catalyst Hub, based in the Greater Boston area and managed by VentureWell, aims to accelerate the commercialization of groundbreaking biomedical solutions. As a spoke, Aspira gains access to potential funding, flexible contracting, and opportunities to provide input on ARPA-H challenge areas and priorities. The company joins a diverse network of organizations aligned with ARPA-H's mission to improve health outcomes through research focus areas such as health science futures, proactive health, scalable solutions, and resilient systems.
Aspira Women's Health Inc. (Nasdaq: AWH) has partnered with Dorsata, a healthcare software company, to develop a protocol workflow tool for the clinical treatment of adnexal masses. This custom care module will be integrated into Dorsata's electronic medical records (EMR) tool, which is used at over 300 clinical sites serving 2,500 clinical users. The module aims to improve the quality and consistency of patient care for women with adnexal masses and is expected to aggregate clinical data from a nationwide network of providers and patients.
Development of the module will begin immediately, with the goal of having the first provider contracted in Q4 2024 and completing all iterative design activities in Q1 2025. This collaboration is expected to help physicians more effectively identify patients who may benefit from innovative tools like biomarker blood tests.
Aspira Women's Health Inc. (Nasdaq: AWH) reported its Q2 2024 financial results. Key highlights include:
- OvaSuiteSM revenue of $2.4 million with 6,471 units sold
- Cash utilization decreased by 16% compared to Q1 2024
- Full year 2024 cash guidance reduced to $13-$14.5 million
- OvaWatch product volume grew 48% year-over-year
- Expanded addressable market to 2-4 million tests per year
- Gross profit margin of 59%
- Raised $4 million through private placement and warrant exercise
- Appointed John Kallassy as interim CFO
The company focuses on developing gynecologic disease diagnostic tools and aims to make OvaSuite the standard of care for adnexal mass diagnosis.
FAQ
What is the current stock price of Aspira Women's Health (AWH)?
What is the market cap of Aspira Women's Health (AWH)?
What is Aspira Women's Health Inc. known for?
What products does Aspira offer?
How effective is OvaWatch?
What is Ova1Plus?
What recent achievements has Aspira made?
What is EndoCheck?
How has Aspira performed financially recently?
Who leads Aspira Women's Health Inc.?
What is OvaMDx?
How does Aspira's test pipeline address women's health issues?
